1-3 of 3
Michael J. Overman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Inducing Hypermutability to Promote Anti–PD-1 Therapy Response

Jason A. Willis, Michael J. Overman
Journal: Cancer Discovery
Cancer Discov (2022) 12 (7): 1612–1614.
https://doi.org/10.1158/2159-8290.CD-22-0492
Published: 06 July 2022
View article titled, Inducing Hypermutability to Promote Anti–PD-1 Therapy Response
Open the PDF for Inducing Hypermutability to Promote Anti–PD-1 Therapy Response in another window
Journal Articles

Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma

Kanwal Raghav, Suyu Liu, Michael J. Overman, Anneleis F. Willett, Mark Knafl, Szu-Chin Fu, Anais Malpica, Seema Prasad, Richard E. Royal, Christopher P. Scally, Paul F. Mansfield, Ignacio I. Wistuba, Andrew P. Futreal, Dipen M. Maru, Luisa M. Solis Soto, Edwin R. Parra Cuentas, Honglei Chen, Pamela Villalobos, Anuj Verma, Armeen Mahvash, Patrick Hwu, Patricia Cortazar, Edward McKenna, Cindy Yun, Shannon Dervin, Katja Schulze, Walter C. Darbonne, Ajaykumar C. Morani, Scott Kopetz, Keith F. Fournier, Scott E. Woodman, James C. Yao, Gauri R. Varadhachary, Daniel M. Halperin
Journal: Cancer Discovery
Cancer Discov (2021) 11 (11): 2738–2747.
https://doi.org/10.1158/2159-8290.CD-21-0331
Published: 01 November 2021
View article titled, Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma
Open the PDF for Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma in another window
Includes: Supplementary data
Journal Articles

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation

David S. Hong, Van K. Morris, Badi El Osta, Alexey V. Sorokin, Filip Janku, Siqing Fu, Michael J. Overman, Sarina Piha-Paul, Vivek Subbiah, Bryan Kee, Apostolia M. Tsimberidou, David Fogelman, Jorge Bellido, Imad Shureiqi, Helen Huang, Johnique Atkins, Gabi Tarcic, Nicolas Sommer, Richard Lanman, Funda Meric-Bernstam, Scott Kopetz
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2016) 6 (12): 1352–1365.
https://doi.org/10.1158/2159-8290.CD-16-0050
Published: 04 December 2016
View article titled, Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with <em>BRAF</em><sup>V600E</sup> Mutation
Open the PDF for Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with <em>BRAF</em><sup>V600E</sup> Mutation in another window
Includes: Supplementary data